Biogen Idec Inc (BIIB) 285.94 $BIIB
Is Perrigo (PRGO) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:00PM CDT
Perrigo (PRGO) is set to report third quarter fiscal 2014 results on May 7 before the market opens.
Sangamo BioSciences Reports First Quarter 2014 Financial Results
PR Newswire - Tue May 06, 3:02PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2014 financial results and accomplishments.
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
Global Biosimilars Market 2014-2018: 10 Companies Dominate this Lucrative Industry
M2 - Tue May 06, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jsnl6q/global) has announced the addition of the "Global Biosimilars Market 2014-2018: 10 Companies Dominate this Lucrative Industry" report to their offering. One of the main drivers in this market is the increasing number of patent expirations. A number of biopharmaceutical patents are due to expire in the near future or have already expired. This has helped propel the growth of vendors in the Global Biosimilars market. Some of the blockbuster drugs that are expected to lose patent expiry are Remicade, Humira, and Rituxan. The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. Further, the report states that one of the key challenges in the market is the risks related to drug failure. Vendors face a high level of risk due to the huge investments involved in the development stage and the possible failure of drugs when launched. Key questions answered in this report: - What will the market size be in 2016/2018 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key vendors dominating this space include: - Biocon Ltd. - Hospira Inc. - Mylan Inc. - Novartis AG - Teva Pharmaceutical Industries Ltd. - Intas Pharmaceuticals Ltd. - Dr. Reddy's Laboratories Ltd. - F. Hoffmann-La Roche Ltd. - 3SBio Inc. - Celltrion Inc. Other vendors mentioned in the report are - Actavis plc - Amgen Inc. - AstraZeneca plc - Baxter International Inc. - Biogen Idec Inc. - Bioton S.A. - Boehringer Ingelheim GmbH - Cipla Ltd. - Coherus Biosciences Inc. - Daiichi Sankyo Co. Ltd. - Emcure Pharmaceuticals Ltd. - GE Healthcare Ltd. - GeneScience Pharmaceuticals Co. Ltd. - GlaxoSmithKline plc - JCR Pharmaceuticals Co. Ltd. - iBio Inc. - LG Life Sciences Co. Ltd. - Merck & Co. Inc. - Pfizer Inc. - Ranbaxy Laboratories Ltd. - Samsung Biologics Co. Ltd. - Sanofi S.A. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/jsnl6q/global
Walgreen Hits Record Close On Sweet Easter Sales
at Investor's Business Daily - Mon May 05, 3:25PM CDT
Walgreen (WAG) sales climbed 8.8% in April to $5.96 billion as more customers visited stores and spent 6% more per visit. Results also got a lift from a later Easter holiday this year than last, the No. 1 U.S. drug store operator said. Shares of...
Acorda Down on Plumiaz CRL - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 2:12PM CDT
Shares of Acorda Therapeutics, Inc. (ACOR) were down 9.8% on the news of the issuance of a Complete Response Letter (CRL) by the FDA for the New Drug Application (NDA) for Plumiaz nasal spray.
Walgreen Shares Climb Sharply in Holiday-Lifted April
at Investor's Business Daily - Mon May 05, 2:10PM CDT
Walgreen (WAG) sales climbed 8.8% in April to $5.96 billion as more customers visited stores and spent 6% more per visit. Results also got a lift from a later Easter holiday this year than last, the company said. Shares of Walgreen, the No. 1 U.S....
Why the Market Is Wrong About Biogen Idec Inc.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 10:12AM CDT
Shares of Biogen Idec were initially flat when the company reported earnings last week but have seen a sell-off since then. The slump in the stock, however, was partially due to an overall downward trend in biotech at the moment, and in this...
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.65% Loss
Comtex SmarTrend(R) - Fri May 02, 3:52PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $280.01 to a high of $290.61. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $281.32 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.65% Sell Off
Comtex SmarTrend(R) - Fri May 02, 3:52PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $280.01 to a high of $290.61. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $281.32 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Sector Performance in April: Gilead Sciences Rising
at The Street - Fri May 02, 8:49AM CDT
The biotech sector was down again, but there's some hopeful signs of a recovery.
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
New TYSABRI(R) Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients
Business Wire - Thu May 01, 6:30AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI(R) (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis (RRMS) patients with confirmed improvement in walking speed (CIWS) relative to placebo at two years. Additional data from observational registry studies show that switching to TYSABRI after experiencing a multiple sclerosis (MS) relapse while taking interferon beta (IFNB) or glatiramer acetate (GA) reduced the risk of future relapses and treatment discontinuation. These data were presented at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia, Pa. (April 26-May 3, 2014).
TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Now Funded in Saskatchewan
CNW Group - Thu May 01, 5:00AM CDT
Biogen Idec Canada announces today that Saskatchewan is the first province in Canada to fund TECFIDERATM (dimethyl fumarate) as an Exception Drug Status (EDS) benefit through the Saskatchewan MS Drugs Program. TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1 )
Biogen Idec to Present at the Deutsche Bank 39th Annual Healthcare Conference
Business Wire - Wed Apr 30, 3:02PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Deutsche Bank 39th Annual Healthcare Conference. The webcast will be live on Wednesday, May 7, 2014 at 10:40 a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
Critical Alerts For Weibo, ExOne, Biogen Idec, Verizon Communications, and Delta Air Lines Released By InvestorsObserver
PR Newswire - Wed Apr 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for WB, XONE, BIIB, VZ, and DAL.
New Data Reinforce Efficacy of TECFIDERA(R) (Dimethyl Fumarate) in MS Patients with High Disease Activity
Business Wire - Wed Apr 30, 6:31AM CDT
New data reinforce the efficacy of TECFIDERA in a wide range of patients with relapsing-remitting multiple sclerosis (RRMS), as well as support its favorable safety and tolerability profile in the real-world setting. These data were presented by Biogen Idec (NASDAQ: BIIB) at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia.
Is Perrigo (PRGO) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:00PM CDT
Perrigo (PRGO) is set to report third quarter fiscal 2014 results on May 7 before the market opens.
Sangamo BioSciences Reports First Quarter 2014 Financial Results
PR Newswire - Tue May 06, 3:02PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2014 financial results and accomplishments.
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
Global Biosimilars Market 2014-2018: 10 Companies Dominate this Lucrative Industry
M2 - Tue May 06, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jsnl6q/global) has announced the addition of the "Global Biosimilars Market 2014-2018: 10 Companies Dominate this Lucrative Industry" report to their offering. One of the main drivers in this market is the increasing number of patent expirations. A number of biopharmaceutical patents are due to expire in the near future or have already expired. This has helped propel the growth of vendors in the Global Biosimilars market. Some of the blockbuster drugs that are expected to lose patent expiry are Remicade, Humira, and Rituxan. The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. Further, the report states that one of the key challenges in the market is the risks related to drug failure. Vendors face a high level of risk due to the huge investments involved in the development stage and the possible failure of drugs when launched. Key questions answered in this report: - What will the market size be in 2016/2018 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key vendors dominating this space include: - Biocon Ltd. - Hospira Inc. - Mylan Inc. - Novartis AG - Teva Pharmaceutical Industries Ltd. - Intas Pharmaceuticals Ltd. - Dr. Reddy's Laboratories Ltd. - F. Hoffmann-La Roche Ltd. - 3SBio Inc. - Celltrion Inc. Other vendors mentioned in the report are - Actavis plc - Amgen Inc. - AstraZeneca plc - Baxter International Inc. - Biogen Idec Inc. - Bioton S.A. - Boehringer Ingelheim GmbH - Cipla Ltd. - Coherus Biosciences Inc. - Daiichi Sankyo Co. Ltd. - Emcure Pharmaceuticals Ltd. - GE Healthcare Ltd. - GeneScience Pharmaceuticals Co. Ltd. - GlaxoSmithKline plc - JCR Pharmaceuticals Co. Ltd. - iBio Inc. - LG Life Sciences Co. Ltd. - Merck & Co. Inc. - Pfizer Inc. - Ranbaxy Laboratories Ltd. - Samsung Biologics Co. Ltd. - Sanofi S.A. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/jsnl6q/global
Walgreen Hits Record Close On Sweet Easter Sales
at Investor's Business Daily - Mon May 05, 3:25PM CDT
Walgreen (WAG) sales climbed 8.8% in April to $5.96 billion as more customers visited stores and spent 6% more per visit. Results also got a lift from a later Easter holiday this year than last, the No. 1 U.S. drug store operator said. Shares of...
Acorda Down on Plumiaz CRL - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 2:12PM CDT
Shares of Acorda Therapeutics, Inc. (ACOR) were down 9.8% on the news of the issuance of a Complete Response Letter (CRL) by the FDA for the New Drug Application (NDA) for Plumiaz nasal spray.
Walgreen Shares Climb Sharply in Holiday-Lifted April
at Investor's Business Daily - Mon May 05, 2:10PM CDT
Walgreen (WAG) sales climbed 8.8% in April to $5.96 billion as more customers visited stores and spent 6% more per visit. Results also got a lift from a later Easter holiday this year than last, the company said. Shares of Walgreen, the No. 1 U.S....
Why the Market Is Wrong About Biogen Idec Inc.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 10:12AM CDT
Shares of Biogen Idec were initially flat when the company reported earnings last week but have seen a sell-off since then. The slump in the stock, however, was partially due to an overall downward trend in biotech at the moment, and in this...
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.65% Loss
Comtex SmarTrend(R) - Fri May 02, 3:52PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $280.01 to a high of $290.61. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $281.32 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.65% Sell Off
Comtex SmarTrend(R) - Fri May 02, 3:52PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $280.01 to a high of $290.61. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $281.32 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Sector Performance in April: Gilead Sciences Rising
at The Street - Fri May 02, 8:49AM CDT
The biotech sector was down again, but there's some hopeful signs of a recovery.
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
New TYSABRI(R) Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients
Business Wire - Thu May 01, 6:30AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI(R) (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis (RRMS) patients with confirmed improvement in walking speed (CIWS) relative to placebo at two years. Additional data from observational registry studies show that switching to TYSABRI after experiencing a multiple sclerosis (MS) relapse while taking interferon beta (IFNB) or glatiramer acetate (GA) reduced the risk of future relapses and treatment discontinuation. These data were presented at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia, Pa. (April 26-May 3, 2014).
TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Now Funded in Saskatchewan
CNW Group - Thu May 01, 5:00AM CDT
Biogen Idec Canada announces today that Saskatchewan is the first province in Canada to fund TECFIDERATM (dimethyl fumarate) as an Exception Drug Status (EDS) benefit through the Saskatchewan MS Drugs Program. TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1 )
Biogen Idec to Present at the Deutsche Bank 39th Annual Healthcare Conference
Business Wire - Wed Apr 30, 3:02PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Deutsche Bank 39th Annual Healthcare Conference. The webcast will be live on Wednesday, May 7, 2014 at 10:40 a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
Critical Alerts For Weibo, ExOne, Biogen Idec, Verizon Communications, and Delta Air Lines Released By InvestorsObserver
PR Newswire - Wed Apr 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for WB, XONE, BIIB, VZ, and DAL.
New Data Reinforce Efficacy of TECFIDERA(R) (Dimethyl Fumarate) in MS Patients with High Disease Activity
Business Wire - Wed Apr 30, 6:31AM CDT
New data reinforce the efficacy of TECFIDERA in a wide range of patients with relapsing-remitting multiple sclerosis (RRMS), as well as support its favorable safety and tolerability profile in the real-world setting. These data were presented by Biogen Idec (NASDAQ: BIIB) at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia.
